AVR

2.27%

$9.00 anteris technologies ltd

Wilbo: Are we still on track for the 17.5m in ADAPT sales this...

First 7 Last

Share
Profile

Follow
drmatt

611 Posts.

122

01/02/18

10:01

Post #: 30727555
Share

Originally posted by Willbo ↑

Hi guys I’ve spoken to Wayne about the last 4c
Answers in red.
Let’s trust this guy he knows what he is talking about !!
Plus he takes time out to respond to questions

With June -December 2017 will that be Fy2017 or will that be a one off?and there be no 1hFy2018 Until July 2018?
As we moved from financial to calendar reporting (predominately to make our financials more digestible to US funds, we had to close out half year 2017 (June to December) and overlap that with the financial year. As of now we are on calendar year and so the reporting (1st HALF) will be reflected as you have stated in July 2018.

With 2m extra expected this coming Quarter in staff cost why is there such a big jump?
Not to be a martyr about it but our staff costs are still relatively low considering the size of the undertaking (we need perspective here as I am a fiscal conservative generally). We still have less heads than we need which means a lot of the team is still (happily) putting in many more hours than they signed up for.

The costs however do reflect new staff, some close out costs (termination obligations ) , and 2017 bonuses. I appreciate a lot of our shareholders struggle with the issue of bonuses , but they are a necessary part of the global healthcare business(and we are contractually obligated to pay them) - and an important aspect of the reward system (and retention process where needed). Although the share price is vexing to say the least , the actual company performance was very good during 2017 (profit up , costs down, revenues up) and as such in most case is well deserved. Keeping in mind we cant run the company without great people - this in turn will drive the share price. The bonus structure is performance based (as such some people didnt earn theirs) but for the most part the company did perform well against its targets. I think for the moment we are at critical mass however as every 1 of our team = 3 of the competitors !

If we get a Vax and a TAVR deal will there be a new guidance for our 20 earnings for 2020?
I expect that if one or both of these come through I will adjust the guidance upwards.

Are we far off getting approval in MENA for 3D? Close -
I believe there may be some initial orders to some markets from next month.

Are we still on track for the 17.5m in ADAPT sales this FY? (4.3m each quarter) seems a big jump from the 2.1 for the December quarter.
Agree- on face value its a decent step up , but the variables that come into play include new reps coming from very specific backgrounds (we couldn’t attract this type of rep 18 months ago), implementation of an industry leading campaign, increasing publications and data , improved company image and credibility (driven by data as well as TAVR which is giving us much better profile in the big institutions). There are always known knowns, and known unknowns, (which we have factored in). Portfolio expansion will also play a role later in the year as well.We will hit the target.

Any news on the tenders for infusions side of the business we Quoted?
No news yet - we are in play but the cycles are proving to be very long with regards to decision making at the hospital level. I am confident the team will succeed in areas where we can compete.

Is it okay if I put your responses in the hot copper forum? Yes

Expand

Wilbo: Are we still on track for the 17.5m in ADAPT sales this FY?

WP: "....We will hit the target."

I am very much looking forward to that statement coming true.

AHZ Price at posting: 25.0¢ Sentiment: Hold Disclosure: Held
28 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 7 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $9.00		Change 0.200(2.27%)		Mkt cap ! $190.2M

Open	High	Low	Value	Volume
$8.90	$9.48	$8.88	$176.7K	19.75K

Buyers (Bids)

No.	Vol.	Price($)
2	590	$8.80

Sellers (Offers)

Price($)	Vol.	No.
$9.40	70	1

View Market Depth

No.	Vol.	Price($)
2	590	8.800
2	2067	8.680
1	260	8.510
1	300	8.500
1	2	8.420

Price($)	Vol.	No.
9.400	70	1
9.430	105	1
9.490	218	1
9.500	250	1
9.850	1000	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

AVR (ASX) Chart

Wilbo: Are we still on track for the 17.5m in ADAPT sales this...

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Wilbo: Are we still on track for the 17.5m in ADAPT sales this...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News